FDA revises ANDA prioritization MAPP

FDA revises ANDA prioritization MAPP

On Thursday, the US Food and Drug Administration took action to encourage generic drug development and…

All therapy areasFocus OnGenericsMAPPRegulationUS FDAUSA

Take a Free Trial

What you get

Access The Pharma Letter's latest news free for 7 days

alt

PLUS... you can receive the Pharma Letter headlines and news roundup email free forever

Become a Subscriber

What you get

Unlimited access to The Pharma Letter site for a whole year
Only £77 per month or £820 per year

alt

  • No-limits access to our site with up-to-the minute news
  • Personalised news and email alerts
  • Online discussion forums and Q&A section
  • RSS news feeds that you can add to your favourite reader, or website
  • Daily news email alert, with the breaking news stories and news roundup

“Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed”

Nigel Brooksby, Chairman, Sanofi aventis UK Ltd

Back to top